Back to Search Start Over

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Authors :
Del Poeta G
Postorino M
Pupo L
Del Principe MI
Dal Bo M
Bittolo T
Buccisano F
Mariotti B
Iannella E
Maurillo L
Venditti A
Gattei V
de Fabritiis P
Cantonetti M
Amadori S
Source :
Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2016 Apr; Vol. 52 (4), pp. 249-60.
Publication Year :
2016

Abstract

Venetoclax (ABT-199) is a small-molecule selective oral inhibitor of the antiapoptotic protein Bcl-2 that promotes programmed cell death of chronic lymphocytic leukemia (CLL) cells regulating the release of proapoptotic factors, such as Smac/Diablo, apoptosis-inducing factor (AIF) and cytochrome c. In April 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to venetoclax for patients diagnosed with CLL with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. This review will focus on the mechanism of action, preclinical studies and clinical development of venetoclax both as a monotherapy and in combination with other drugs for CLL in the current milieu of therapy dominated by novel tyrosine kinase inhibitors such as ibrutinib and idelalisib.<br /> (Copyright 2016 Prous Science, S.A.U. or its licensors. All rights reserved.)

Details

Language :
English
ISSN :
1699-3993
Volume :
52
Issue :
4
Database :
MEDLINE
Journal :
Drugs of today (Barcelona, Spain : 1998)
Publication Type :
Academic Journal
Accession number :
27252989
Full Text :
https://doi.org/10.1358/dot.2016.52.4.2470954